We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+9.4%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$958M
AUM Growth
+$3.46M
Cap. Flow
+$6.87M
Cap. Flow %
0.72%
Top 10 Hldgs %
27.27%
Holding
97
New
7
Increased
32
Reduced
18
Closed
4

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$10.5M
2
MDT icon
Medtronic
MDT
+$8.92M
3
TECH icon
Bio-Techne
TECH
+$7.15M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.83M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.66M

Top Sells

Rank Stock Value
1
ABMD
Abiomed Inc
ABMD
+$21.7M
2
ISRG icon
Intuitive Surgical
ISRG
+$11M
3
UNH icon
UnitedHealth
UNH
+$8.9M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$8.1M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.62M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Industrials 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHAT icon
76
Phathom Pharmaceuticals
PHAT
$698M
$2.64M 0.28%
235,210
– –
SGMO
77
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.57M 0.27%
820,000
– –
NVCR icon
78
NovoCure
NVCR
$2.04B
$2.57M 0.27%
35,000
– –
NUVL
79
DELISTED
Nuvalent
NUVL
$2.38M 0.25%
+80,000
New +$2.23M
MRSN
80
DELISTED
Mersana Therapeutics
MRSN
$2.34M 0.24%
+16,000
New +$2.7M
ALLO icon
81
Allogene Therapeutics
ALLO
$739M
$2.14M 0.22%
340,000
– –
GTHX
82
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$2.01M 0.21%
370,000
– –
HCAT icon
83
Health Catalyst
HCAT
$133M
$1.91M 0.2%
180,000
– –
IONS icon
84
Ionis Pharmaceuticals
IONS
$9.29B
$1.89M 0.2%
50,000
– –
RIGL icon
85
Rigel Pharmaceuticals
RIGL
$773M
$1.84M 0.19%
122,508
– –
NTLA icon
86
Intellia Therapeutics
NTLA
$1.67B
$1.74M 0.18%
50,000
– –
STXS icon
87
Stereotaxis
STXS
$145M
$1.65M 0.17%
797,330
– –
ISRG icon
88
Intuitive Surgical
ISRG
$141B
$1.33M 0.14%
5,000
-45,000
-90% -$11M
NKTR icon
89
Nektar Therapeutics
NKTR
$2.53B
$1.24M 0.13%
36,667
– –
NKTX icon
90
Nkarta
NKTX
$166M
$1.2M 0.13%
200,000
– –
EPIX
91
DELISTED
ESSA Pharma
EPIX
$945K 0.1%
375,000
– –
IGMS
92
DELISTED
IGM Biosciences
IGMS
$851K 0.09%
+50,000
New +$1M
RPID icon
93
Rapid Micro Biosystems
RPID
$86.3M
$339K 0.04%
300,000
– –
GH icon
94
Guardant Health
GH
$22.3B
– –
-65,000
Closed -$3.22M
PGNY icon
95
Progyny
PGNY
$2.06B
– –
-90,000
Closed -$4M
ABMD
96
DELISTED
Abiomed Inc
ABMD
– –
-85,900
Closed -$21.7M
HZNP
97
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-130,000
Closed -$8.1M
1 2 3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rhenman & Partners Asset Management held 97 positions worth $958M, up 0.36% from $955M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q4 2022 filing shows 7 new, 32 increased, 18 reduced and 4 closed positions. Its largest new stake was Bio-Techne: 90,000 shares worth $7.46M. The largest sale was Abiomed Inc, an estimated $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q4 2022 buy was Bio-Techne: 90,000 shares worth $7.46M.
  • Rhenman & Partners Asset Management added most to HCA Healthcare in Q4 2022, an estimated $10.5M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2022 reduction was Intuitive Surgical, cutting an estimated $11M.
  • Rhenman & Partners Asset Management fully exited Abiomed Inc in Q4 2022, selling an estimated $21.7M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $958M portfolio in Q4 2022.
  • Rhenman & Partners Asset Management opened 7 new positions and closed 4 in Q4 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 0.36% quarter-over-quarter to $958M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.